Research

Diabetes mellitus in HIV-infected patients on antiretroviral therapy

D Moyo, G Tanthuma

Abstract


 

 Background. There is little in the literature on HIV and diabetes mellitus (DM) in sub-Saharan Africa. 

Objective. To assess the characteristics of HIV and DM in patients on antiretroviral therapy (ART) in Botswana. 

Methods. A retrospective case-control study was conducted at 4 sites. Each HIV-infected patient with DM (n=48) was matched with 2 HIV-infected controls (n=108) by age (±2 years) and sex. Primary analysis was conditional logistic regression to estimate univariate odds and 95% confidence intervals (CIs) for each characteristic. 

Results. There was no significant association between co-morbid diseases, tuberculosis, hypertension or cancer and risk of diabetes. DM patients were more likely to have higher pre-ART weight (odds ratio (OR) 1.09; 95% CI 1.04 - 1.14). HIV-infected adults >70 kg were significantly more likely to have DM (OR 12.30; 95% CI 1.40 - 107.98). Participants on efavirenz (OR 4.58; 95% CI 1.44 - 14.57) or protease inhibitor therapy (OR 20.7; 95% CI 1.79 - 240.02) were more likely to have DM. Neither mean pre-ART CD4 cell count (OR 1.0; 95% CI 0.99 - 1.01) nor pre-ART viral load >100 000 copies/ml (OR 0.71; 95% CI 0.21 - 2.43) were associated with a significant risk of diabetes. 

Conclusions. These findings suggest a complex interrelation among traditional host factors and treatment-related metabolic changes in the pathogenesis of DM inpatients receiving ART. Notably, pre-ART weight, particularly if >70 kg, is associated with the diagnosis of diabetes in HIV-infected patients in Botswana. 


Authors' affiliations

D Moyo, Institute for Health Sciences, Gaborone, Botswana

G Tanthuma, Institute for Health Sciences, Gaborone, Botswana

Full Text

PDF (112KB)

Cite this article

South African Medical Journal 2014;104(1):37-39.

Article History

Date submitted: 2018-07-09
Date published: 2018-07-09

Article Views

Abstract views: 314
Full text views: 130

Comments on this article

*Read our policy for posting comments here